Cholecystokinin modulates both the development and the expression of behavioral sensitization to amphetamine in the rat

Psychopharmacology

Volumn 151, Issue 2-3, 2000, Pages 283-290

  Wunderlich, G R ^a   DeSousa, N J ^a   Vaccarino, F J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amphetamine; Cholecystokinin; Devazepide; L 365,26 0; Psychostimulant; Sensitization

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; AMPHETAMINE; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DEVAZEPIDE; PSYCHOSTIMULANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; LIMBIC SYSTEM; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BENZODIAZEPINONES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOLECYSTOKININ; DEVAZEPIDE; MALE; MOTOR ACTIVITY; PHENYLUREA COMPOUNDS; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0033838335     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000445     Document Type: Article

References (53)

1. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay
2. Biochemical and pharmacological characterization of an extremely potent and selective non-peptide CCK antagonist
3. 3[H]-L365,260: A new potent and selective brain CCK (CCK(B)) and gastrin receptor radioligand
4. Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion
5. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway
6. Biological actions of cholecystokinin
7. Antagonists of central and peripheral behavioral actions of cholecystokinin octapeptide
8. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCK(B) receptors by using a new highly potent CCK analog, BC 264
9. Blockade of CCK(A) receptors does not affect amphetamine- or dark phase-induced locomotor activity
10. The expression of behavioral sensitization to amphetamine: Role of CCK(A) receptors
11. Increases of CCK mRNA and peptide in different brain areas following acute and chronic administration of morphine
12. The effect of repeated doses of cocaine on the dog
13. Cholecystokinin octapeptide: Vesicular localization and calcium dependent release from rat brain in vitro
14. 2 DA receptor stimulation
15. Newly synthesized cholecystokinin in subcellular fractions of the rat brain
16. Blockade of morphine place conditioning by the CCK(A) receptor antagonist devazepide
17. Morphine place conditioning is differentially affected by CCK(A) and CCK(B) receptor antagonists
18. Evidence for the contribution of CCK(B) receptor mechanisms to individual differences in amphetamine-induced locomotion
19. A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: Evidence from immunohistochemistry combined with retrograde tracing
20. Coexistence of peptides with classical neurotransmitters
21. Cholecystokinin-dopamine coexistence: Electrophysiological actions corresponding to cholecystokinin receptor sub-type
22. Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission
23. Devazepide, a CCK(A) receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity
24. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity
25. Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine
26. Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine
27. Effect of pretreatment with amphetamine on the interaction between amphetamine and dopamine neurons in the nucleus accumbens
28. Contrasting effects on methamphetamine sensitization of ceruletide, a cholecystokinin-like decapeptide, and haloperidol
29. 8 and of the CCK(B)-selective agonist BC264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: A microdialysis study in freely moving rats
30. Cholecystokinergic innervation of nucleus accumbens subregions
31. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms
32. Two brain cholecystokinin receptors: Implications for behavioral actions
33. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats
34. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants
35. Behavioral sensitization is accompanied by an enhancement in amphetamine-stimulated dopamine release from striatal tissue in vitro
36. Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis
37. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: A microdialysis study in freely moving rats
38. Predictive reward signal of dopamine neurons
39. Long-term administration of d-amphetamine: Progressive augmentation of motor activity and stereotypy
40. Animal models of stimulant-induced psychosis
41. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis
42. Microinjections of Sch-23390 into the ventral tegmental area and substantia nigra pars reticulata attenuate the development of sensitization to the locomotor activating effects of systemic amphetamine
43. Autoradiographic localization of CCK-8 binding sites in the rat brain: Effects of chronic methamphetamine administration on these sites
44. Experimental cocaine addiction
45. Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors
46. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: Evidence for rostral-caudal differences in accumbens CCK function
47. 1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area
48. The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine
49. 3H]dopamine efflux from rat nucleus accumbens
50. 3H]dopamine from the nucleus accumbens of the rat
51. Repeated administration of MDMA down-regulates preprocholecystokinin mRNA expression but not tyrosine hydroxylase mRNA expression in neurones of the rat substantia nigra
52. Microinjection of PD-140,548, a CCK(A) antagonist, into the caudal nucleus accumbens attenuates the locomotor response to amphetamine in amphetamine-sensitized animals
53. Accelerated expression of cholecystokinin gene in the brain of rats rendered tolerant to morphine